<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyGuido Marcucci, Clara D. Bloomfield, Meir Wetzler et al.|Journal of Clinical Oncology|2010Cited by 764
Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B StudyHeiko Becker, Clara D. Bloomfield, Guido Marcucci et al.|Journal of Clinical Oncology|2009Cited by 342
<i>TET2</i> Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyKlaus H. Metzeler, Clara D. Bloomfield, Kati Maharry et al.|Journal of Clinical Oncology|2011Cited by 321
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySusan P. Whitman, Clara D. Bloomfield, Kati Maharry et al.|Blood|2010Cited by 231
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Clara D. Bloomfield, Guido Marcucci et al.|Blood|2010Cited by 116